Inconvenience but no great hardship is experienced if patients are unable to be discharged the same day in that they must be transferred for complete recovery to the adjacent inpatient sister hospital (a very infrequent occurrence).
Discussion
In spite of some disagreement about the precise definition of day surgery, it was agreed that all surgeons should keep an accurate record of the numbers of the patients undergoing surgical treatment which does not involve an overnight stay and that the nature of the problem, the treatment and the style of anaesthesia should also be included. Details of surgical treatment as coded and retrieved by HAA or any other clerk-based system are notoriously inaccurate and misleading and cannot be reliably used for planning purposes.
To make optimum use of day surgery close association was recommended with a planned 'Day Investigation' unit.
The main line of discussion concerned the apparent reluctance of many surgeons to change their surgical practice to do more day surgical procedures. The nursing profession and the Faculty of Anaesthetists have both adapted their training and even their examination systems to include working practice tailored to a day surgery environment; yet, in spite of the exhortations and encouragements to change, Journal of the Royal Society of Medicine Volume 81 April 1988 239 relatively few surgical enthusiasts seriously carry out day surgery while experience and management in this field is still not considered a necessary part of the training of a surgeon compared to other countries with compararable health care resources in which day surgery is a widely acceptable norm. In the present shortage of nurses and other essential staff required for inpatient care, day surgery treatment is the only means of guaranteeing a patient a bed and treatment at their convenience rather than the inconvenience of the hospital regardless of yellow, blue or red alerts. Staff are easy to recruit, morale is high and working in a Day Surgery Unit can actually he fun. A cynical note was expressed that the more entrenched surgeons are unlikely to do more day surgery until they are under compulsion or have some sort of incentive to do so. c sr Ward In 1796 Edward Jenner inoculated James Phipps with the 'lymph' taken from cowpox vesicles on the finger of dairymaid Sarah Nelmes. By showing that the boy was then immune to smallpox infection, Jenner became the forefather of modern vaccination.
Vaccination still remains the best possible approach to infectious disease control, but how vaccines protect is still not fully understood. The recent flowering of immunology may explain immunity in terms of host defence mechanisms and immunopathogenesis and reveal how vaccines work.
Dr G Schild (NffiS)showed how new biotechnology, including recombinant DNA and hybridoma techniques have led to the sequencing, manipulation and controlled expression ofmicrobial genes. Viral vaccines have been developed in two ways: The first is the production of non-replicating antigens as synthetic oligopeptides, anti-idiotypes or through controlled gene expression in eukaryotic cells. The second, as live vaccines either in the form of attenuated strains resulting from precise genetic modifications ofvirulent viruses, or by insertion of the gene coding for a foreign antigen into a live virus vector.
However, there are scientific challenges to he met in implementing these approaches: Small oligopeptides may not have the correct configuration to confer antigenicity and generally require appropriate carrier proteins and adjuvants; while controlled gene expression has allowed the development of efficacious vaccines, as in the case of hepatitis B surface antigen production by yeast cells, yields are variable and glycosylation does not occur in prokaryotic cells. The alternative use of transformed mammalian cell lines carries the risk of contamination with oncogenic DNA or retroviruses, thus the products need to be highly purified. When considering the use oflive recombinant viruses, vaccinia is a potent tool for inducing an immune response.
To exploit new technology, knowledge of immunobiology must simultaneously increase. Dr Schild referred to his recent work on determining the basis of antigenicity and virulence of poliovirus. By mapping mutant strains of the type 3 virus, he identified the amino acid sequences that determine resistance to a panel of neutralizing monoclonal antibodies. This led to the location of three antigenic sites on poliovirus (VP1·3) of which VP1 is immunodominant. Further studies comparing nucleotide differences between a virulent, an attenuated and a revertant wild-type strain have elucidated two nucleotides that determine virulence. This work could ultimately lead to new approaches to vaccine design. (St Mary's Hospital, London) pointed out that although the efficacy of vaccinia in the WHO programme ofsmallpox eradication is not in question, the origin ofthe smallpox vaccine and its phylogenetic relationship to other pox viruses is still unknown. Many different strains of vaccinia virus exist which each show marked differences in pock production and other aspects of pathogenicity'.
Vaccinia recombinants are formed by the insertion of a foreign gene, flanked by vaccinia specific promoter sequence, in the thymidine kinase (TK) region of native vaccinia. The most extensively characterized laboratory strain, vaccinia WR, is also the most pathogenic in animal models and displays marked neurovirulence. However,recombinants based on the insertion of foreign genes into the TK region of the WR vaccinia genome, result in TK·negative mutants with greatly decreased neurovirulence'', Dr M Mackett (CRC, Manchester) continued by explaining that currently available live attenuated vaccines can be engineered to produce important vaccine antigens of other viruses", An example of this is use of vaccinia virus to express the major glycoprotein membrane antigen (gp350) of Ebstein-Barr virus (EBV)4. Immunization of rabbits led to production of EBV neutralizing antibody but did not establish whether there was protection against disease. Cotton top tamarins develop malignant lymphomas when challenged with an appropriate dose of EBV. A recombinant based on the vaccine strain of vaccinia expressed gp350 but did not protect the tamarins. However, a laboratory strain recombinant expressing gp350 gave protection against malignant lymphomas in the absence of circulating anti-gp350. Various vaccinia recombinants have been shown to generate cytotoxic'I'cells against the foreign gene product and it is possible that protection in this system was due to cytotoxic T-cells raised against the gp350.
To date only two cases of human vaccination with recombinant vaccines have been recorded: The first, an accidental inoculation of a VZV recombinant resulted in good antibody synthesis; the second is the use of a vaccinia recombinant carrying the glycoprotein antigen of HIV by Daniel Zagury. Despite these cases it remains open to debate as to whether this approach will be used widely.
Dr F Hay (Middlesex Hospital, London) spoke on anti-idiotype vaccines which are dependent on the capacity of an antibody to recognize determinants on other antibodies. Whilst some anti-idiotypee are directed towards the combining site, and so mimic antigen by forming an internal image, others may be directed towards framework components and manipulate groups of antibodies in ways independent of antigen binding. Both anti-idiotypea may have therapeutic uses.
By raising anti·idiotypes to mouse monoclonal antibodies to hepatitis B surface antigen and selecting ones that competitively inhibit binding of original antigen, internal image monoclonal anti-ldiotypes have been identified. The affinity of these is higher than for native antigen, closely mimicking the hepatitis B. antigenic epitope. The proportion of antibody binding is much lower than that which binds antigen, indicating that it represents only a small fraction of the normal response. Nevertheless, immunization with polyclonal anti-idiotypes have shown protection against hepatitis B infection in chimpanzees.
The commercial applications ofthe approach are not established, since peptides and recombinants are cheaper and easier to manufacture. Nevertheless, anti-idiotypes could have uses particularly in the production of vaccines to polysaccharide antigens where reponses are poor in young children. Using an internal image anti-idiotype, aT-independent antigen could be converted into a T-dependent one. Experimentally, in neonatal mice, anti-idiotypes to anti-polysaccharide antibodies of Escherichia coli have resulted in strong protective immunity to E. coli infections.
The development of bacterial vaccines has been a slow,often empirical processbecause ofthe complexity of bacteria. Whooping cough is an example where refinement of an acellular vaccine is already taking place. Dr A Robinson (CAMR) suggested that, ideally, a vaccine should protect against both initiation of infection through attachment to specific cellular sites, and against effects of disease, often mediated by toxins," Bordetella pertussis components involved in pathogenesis include lymphocytosis promoting factor (LPF, pertussis toxin), lipopoly-aaccharidea (LPS), filamentous haemagglutinin (FHA), agglutinogens, outer membrane proteins, adenylate cyclase and cytotoxins. Those componentsresponsiblefor protection must be identified and incorporated into the vaccine. Acellular pertussis vaccines have been used in Japan since 1981. The principal constituents are FHA and LPF, obtained from culture supernatant but not separately purified. Consequently, the composition of the vaccines vary but protection has been shown in small groups of children in home-contact studies. Dr Robinson then compared the Japanese vaccines with the new English vaccine made at Porton. The three main components of this vaccine are FHA and agglutinogens, important for the adhesion of bacteria, and LPF, responsible for many of the toxic effects of the disease. These have been separately purified, detoxified and combined in equal proportions with an adjuvant to form an acellular vaccine. Toxicity and potency testing in animal models has shown the product has less toxicity than whole cell vaccine and produces good antibody responses to all three components. Preliminary human trials in adult volunteers resulted in neutralizing antibody production with only minor side-effects", Field trials in infants are planned.
Dr D Jones (PHLS, Manchester) began his talk on meningococcal vaccines by emphasizing the three factors which control the occurrence of disease; the virulence of the strains circulating through the community, the mobility of these strains and lastly, the level of herd immunity. It is herd immunity that we can hope to influence with a vaccination programme. At present, the available polysaccharide vaccines are unlicensed in the UK but are effective against group A and C meningococci. However, polysaccharide vaccines against group B species are not effective, but it appears that antibodies to the immunodominant outer membrane proteins (OMP) are protective. These are type specific within the group B class of meningococci and epidemiologically, it seems that the emergence of a new serotype may lead to a mini-epidemic. Polysaccharide vaccines are ineffective in children below the age of two, who form a large part of the at risk population. It may be that if the vaccines were conjugated to carrier proteins, perhaps OMP, they would be more efficient.
The current low incidence of meningitis in the UK does not warrant broad-scale vaccination, although since 1984 the numbers of notifications of meningococcal meningitis have been climbing steadily. The emergence of a new group B serotype 15, combined with a slow but steady rise in group C disease is mainly responsible. Within the type 15 group B meningococcus, a sulphonamide resistant clone phenotypically also expressing the type 16 subgroup has been identified. This shows an age reversal in its target population, with disease predominantly in the 10-24 year age group.
Vaccines against meningococci, therefore must incorporate not only group A and C polysaccharides but also OMP of the prevalent group B types. The group B type is likely to vary with time and place, so vaccine components will have to be regularly reviewed. Non-typable group B meningococci are now responsible for an increasing proportion of cases, suggesting the emergence of a new serotype that may replace serotype 15 as the dominant strain.
The oral route is possibly the most desirable for vaccines particularly against enteric pathogens. This route mimics the natural route ofinfection and triggers local defence mechanisms. Dr G Dougan (Wellcome Research Laboratories) discussed the potential of live oral bacterial vaccines. The rationale has been to produce attenuated mutants by standardized manipulations of bacteria in a reproducible fashion. Much work has concentrated on auxotrophic markers for attenuation in Salmonellae, using mutations in biosynthetic pathways in bacteria not present in mammalian cells, such as aromatic or purine pathways, to produce stable dependent strains. The resulting loss of pathogenicity is generally in the 3-8 log range when measured using the LD 50 of the mutant organism. In an animal model, ingestion of a lethal dose of S. typhimurium caused infection in the liver and spleen and death within 10-14 days. However, ingestion of an attenuated auxotrophic mutant resulted in colonization within macrophages of the lymphoreticular system with gradual clearing ofthe organism over five to six weeks, and subsequent resistance to challenge with the virulent strain. Immunity produced was both cell-mediated and humoral with not only local IgA production at all mucosal surfaces but also good serum antibody responses. Consequently, mutant Salmonellae could have potential as vectors for antigens from bacteria, as varied as Neisseriae or mycobacteria. Professor T Lehner (UMDS, Guy's Hospital, London) considered the immunization against colonization by Streptococcus mutans and stressed that the minimum requirement of a synthetic peptide vaccine is to elicit both B and T-cell responses. It must, therefore contain immunodominant epitopes recognizing not only T helper, T suppressor subclasses and B-cells, but also agretopes binding to HLA class II molecules to effect efficient antigen presentation. Investigations into the antigenicity of Strep. mutans identified a peptide that was immunogenic. Amino acid analysis has enabled several synthetic peptides to be developed based on this structure which elicit antibody responses that cross-react with native antigen. However, initial studies in non-human primates revealed that the peptide did not appear to contain a T helper determinant and required crosslinking to tetanus toxoid and an adjuvant to stimulate a response. Local immunization by applying the peptide to the gingival margin resulted in a small but detectable rise in local IgG and IgA, and protected against colonization by Strep. mutans during a high sugar diet.
Alternatively, passive immunization using a monoclonal antibody to Strep. mutans applied to the teeth and gums prior to challenge is protective. Experiments in monkeys have shown a decrease in the incidence of dental caries using these monoclonals, and similarly, in man decreased colonization rates in the oral cavity.
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